A widespread campaign to vaccinate against respiratory syncytial virus (RSV) is drawing to a close in many areas, following a significant decline in viral circulation in recent weeks. The initiative, which began in September 2025, aimed to protect those most vulnerable – particularly newborns and infants – as the winter season approached. This is crucial as RSV can cause severe respiratory illness, especially in young children.
The campaign focused on providing preventative treatments like Abrysvo, Beyfortus, and Synagis (for hospital use) to reduce serious RSV infections. Pregnant women, newborns, and infants were specifically targeted due to their increased risk of respiratory complications from the virus.
Campaign End Dates Vary by Region
End dates for the campaign were determined based on local epidemiological conditions. In mainland France, as well as Saint Barthélemy and Saint Martin, the campaign will conclude on February 20. Guadeloupe and Martinique will continue vaccinations until March 31, while Mayotte will run its campaign through May 31.
Healthcare professionals may continue to administer the immunization on a case-by-case basis until February 28, 2026, in mainland France, Saint Barthélemy, and Saint Martin, following standard billing procedures, to address individual clinical situations or specific local outbreaks.
Continued Vaccination Efforts in Some Areas
In French Guiana, the vaccination and immunization campaign will continue without a set end date. Due to year-round RSV circulation, continuous availability of preventative treatments is recommended there. This highlights the importance of ongoing surveillance and proactive measures in regions with persistent viral activity.
For Réunion, further details regarding the continuation of the campaign will be communicated later, depending on the evolution of the local health situation.
Decision Based on Epidemiological Analysis
The French Directorate General of Health consulted with Santé publique France to determine the campaign end dates. This decision was based on an analysis of the epidemiological trends observed across mainland France and all overseas departments and regions, confirming a decrease in viral circulation in most areas. The findings could inform future public health strategies for managing RSV outbreaks.
